146 related articles for article (PubMed ID: 19717985)
1. Atrasentan (ABT-627) enhances perfusion and reduces hypoxia in a human tumor xenograft model.
Yang KM; Russell J; Lupu ME; Cho H; Li XF; Koutcher JA; Ling CC
Cancer Biol Ther; 2009 Oct; 8(20):1940-6. PubMed ID: 19717985
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of changes in tumor hypoxia.
Russell J; Carlin S; Burke SA; Wen B; Yang KM; Ling CC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1177-86. PubMed ID: 19251089
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive molecular imaging of hypoxia in human xenografts: comparing hypoxia-induced gene expression with endogenous and exogenous hypoxia markers.
He F; Deng X; Wen B; Liu Y; Sun X; Xing L; Minami A; Huang Y; Chen Q; Zanzonico PB; Ling CC; Li GC
Cancer Res; 2008 Oct; 68(20):8597-606. PubMed ID: 18922936
[TBL] [Abstract][Full Text] [Related]
4. Changes in tumor hypoxia induced by mild temperature hyperthermia as assessed by dual-tracer immunohistochemistry.
Sun X; Li XF; Russell J; Xing L; Urano M; Li GC; Humm JL; Ling CC
Radiother Oncol; 2008 Aug; 88(2):269-76. PubMed ID: 18538874
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles.
Koch CJ; Hahn SM; Rockwell K; Covey JM; McKenna WG; Evans SM
Cancer Chemother Pharmacol; 2001 Sep; 48(3):177-87. PubMed ID: 11592338
[TBL] [Abstract][Full Text] [Related]
6. Tracer level electrophilic synthesis and pharmacokinetics of the hypoxia tracer [(18)F]EF5.
Eskola O; Grönroos TJ; Forsback S; Tuomela J; Komar G; Bergman J; Härkönen P; Haaparanta M; Minn H; Solin O
Mol Imaging Biol; 2012 Apr; 14(2):205-12. PubMed ID: 21448777
[TBL] [Abstract][Full Text] [Related]
7. DCE-MRI of the hypoxic fraction, radioresponsiveness, and metastatic propensity of cervical carcinoma xenografts.
Ellingsen C; Hompland T; Galappathi K; Mathiesen B; Rofstad EK
Radiother Oncol; 2014 Feb; 110(2):335-41. PubMed ID: 24231244
[TBL] [Abstract][Full Text] [Related]
8. Importance of antibody concentration in the assessment of cellular hypoxia by flow cytometry: EF5 and pimonidazole.
Koch CJ
Radiat Res; 2008 Jun; 169(6):677-88. PubMed ID: 18494550
[TBL] [Abstract][Full Text] [Related]
9. Detection of hypoxia by [18F]EF5 in atherosclerotic plaques in mice.
Silvola JM; Saraste A; Forsback S; Laine VJ; Saukko P; Heinonen SE; Ylä-Herttuala S; Roivainen A; Knuuti J
Arterioscler Thromb Vasc Biol; 2011 May; 31(5):1011-5. PubMed ID: 21372297
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma: efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan.
Rosanò L; Spinella F; Di Castro V; Natali PG; Bagnato A
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S132-5. PubMed ID: 15838262
[TBL] [Abstract][Full Text] [Related]
11. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J
J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of tumor perfusion and oxygenation by carbogen and nicotinamide during single- and multifraction irradiation.
Fenton BM; Lord EM; Paoni SF
Radiat Res; 2000 Jan; 153(1):75-83. PubMed ID: 10630980
[TBL] [Abstract][Full Text] [Related]
13. Endothelin-A-receptor antagonism with atrasentan exhibits limited activity on the KU-19-19 bladder cancer cell line in a mouse model.
Herrmann E; Tiemann A; Eltze E; Bolenz C; Bremer C; Persigehl T; Hertle L; Wülfing C
J Cancer Res Clin Oncol; 2009 Oct; 135(10):1455-62. PubMed ID: 19430814
[TBL] [Abstract][Full Text] [Related]
14. Detection of hypoxic cells with the 2-nitroimidazole, EF5, correlates with early redox changes in rat brain after perinatal hypoxia-ischemia.
Bergeron M; Evans SM; Sharp FR; Koch CJ; Lord EM; Ferriero DM
Neuroscience; 1999; 89(4):1357-66. PubMed ID: 10362320
[TBL] [Abstract][Full Text] [Related]
15. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
Marzola P; Degrassi A; Calderan L; Farace P; Nicolato E; Crescimanno C; Sandri M; Giusti A; Pesenti E; Terron A; Sbarbati A; Osculati F
Clin Cancer Res; 2005 Aug; 11(16):5827-32. PubMed ID: 16115922
[TBL] [Abstract][Full Text] [Related]
16. 18F-EF5 PET Is Predictive of Response to Fractionated Radiotherapy in Preclinical Tumor Models.
Ali R; Apte S; Vilalta M; Subbarayan M; Miao Z; Chin FT; Graves EE
PLoS One; 2015; 10(10):e0139425. PubMed ID: 26431331
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5.
Ziemer LS; Evans SM; Kachur AV; Shuman AL; Cardi CA; Jenkins WT; Karp JS; Alavi A; Dolbier WR; Koch CJ
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):259-66. PubMed ID: 12552344
[TBL] [Abstract][Full Text] [Related]
18. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
Lee CG; Heijn M; di Tomaso E; Griffon-Etienne G; Ancukiewicz M; Koike C; Park KR; Ferrara N; Jain RK; Suit HD; Boucher Y
Cancer Res; 2000 Oct; 60(19):5565-70. PubMed ID: 11034104
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia and VEGF mRNA expression in human tumors.
Ziemer LS; Koch CJ; Maity A; Magarelli DP; Horan AM; Evans SM
Neoplasia; 2001; 3(6):500-8. PubMed ID: 11774032
[TBL] [Abstract][Full Text] [Related]
20. Co-localization of hypoxia and apoptosis in irradiated and untreated HCT116 human colon carcinoma xenografts.
Koch CJ; Chasan JE; Jenkins WT; Chan CY; Laughlin KM; Evans SM
Adv Exp Med Biol; 1998; 454():611-8. PubMed ID: 9889941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
